Significant effect of tirofiban combined with ureklin in the treatment of patients with APCI
Objective:To investigate the effectiveness of tirofiban combined with ureklin in the treatment of patients with acute progressive cerebral infarction(APCI),and to analyze the risk factors that affect the efficacy of patients.Methods:A total of 160 cases of APCI were selected as the research objects and randomly divided into an observation group and a control group,80 cases in each group.The control group was treated with urinary kallidinogenase,and the observation group was treated with tirofiban combined with urinary kallidinogenase.The clinical efficacy,NIHSS score,Barthel score,Mrs score and adverse reactions were compared between the two groups.Univariate analysis and logistic regression analysis were used to analyze the risk factors affecting the curative effect.Results:The effective rate(92.50％vs.81.25％)and good prognosis rate(91.25％vs.80.00％)in the observation group were significantly higher than those in the control group(P＜0.05).After treatment,the NIHSS score in the two groups was significantly reduced,while the Barthel index was significantly in-creased.Among them,the NIHSS score and Barthel index in the observation group were significantly better than those in the control group at the 3rd,7th,and 14th day of treatment(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Univariate and multivariate Logistic regression analysis showed hyper-tension(OR=1.881,95％CI:1.113～3.181),diabetes(OR=1.657,95％CI:i.117～2.457),atherosclerotic plaque in the carotid artery(OR=2.208,95％CI:1.285～3.792)were the independent risk factors that affected the efficacy of patients.Conclusion:Tirofiban combined with ureklin has a significant effect in the treatment of patients with APCI,which can significantly improve neurological deficit symptoms and patient prognosis.
NETL
NSTL
万方数据
